Adv Sci (Weinh) July 2023 PMID 37142882

KMT2D Deficiency Promotes Myeloid Leukemias which Is Vulnerable to Ribosome Biogenesis Inhibition.

Jing Xu, Ailing Zhong, Shan Zhang, Mei Chen, Lanxin Zhang, Xiaohang Hang, Jianan Zheng, Baohong Wu, Xintong Deng, Xiangyu Pan, Zhongwang Wang, Lu Qi, Kaidou Shi, Shujun Li, Yiyun Wang

Mentions

2
Peak: 1 in May 2023
across 2 sources since May 2023

Extended reach

387
potential audience

Total likes

2

Video views

227

Mentions per month

May 2023 – Oct 2023

Where it's discussed

  • X / Twitter1 posts
  • YouTube1 videos

AI synopsis

What people are saying

The discussion is very limited, focusing solely on the inclusion of RRIDs and open science practices, which suggests some appreciation for methodological clarity but little interest in the broader scientific implications of the research. The tone is appreciative but lacks depth or critical analysis, contributing to the neutral scores across agreement and impact.

AgreementNeither agree nor disagree

The single post expresses appreciation for the authors including RRIDs, aligning with open science practices, but overall, there is limited discussion on the article's findings, leading to a neutral agreement score.

InterestModerate interest

The post shows some interest by acknowledging methodological transparency, indicating a mild engagement with the article's content.

EngagementModerate engagement

The discussion reflects a basic recognition of the authors' transparency, but lacks deep analysis or engagement with the implications of the research findings.

ImpactNeutral impact

The reply highlights a positive aspect of the publication (method transparency), but because there is only one post, the perceived overall impact on the community is minimal.

Abstract in brief

  • KMT2D is often mutated or downregulated in acute myeloid leukemia (AML), and its loss accelerates leukemia development by increasing ribosome production and cell growth.
  • The deficiency of KMT2D activates the mTOR pathway, which promotes abnormal ribosome biogenesis through the regulation of the gene Ddit4.
  • Targeting ribosome production with a drug called CX5461 can effectively slow down AML growth and improve survival in mice with KMT2D loss, highlighting a potential treatment strategy.]

Top posts

Most liked on X and Bluesky
RRID Robot
@RobotRrid · X

The authors of "KMT2D Deficiency Promotes Myeloid Leukemias which…" (https://t.co/4FnXQeQNCt) included RRIDs in their paper! Thank you for making your #methodsmatter. #accelerateopenscience

May 11, 2023 · 161 followers View post →

All mentions

RRID Robot
@RobotRrid · X

The authors of "KMT2D Deficiency Promotes Myeloid Leukemias which…" (https://t.co/4FnXQeQNCt) included RRIDs in their paper! Thank you for making your #methodsmatter. #accelerateopenscience

May 11, 2023 · 161 followers View post →